About Us

Healers Nutraceuticals Private Limited [HNPL], established in the year 1999 is a Product Development and Profit making Company.

PRODUCT DEVELOPMENT COMPANY.

was incorporated in 1999 with a sole aim to develop newer molecules from natural sources that have preventive and curative role. HNPL sponsors research, and develops innovative products of natural origin, builds up backup technical data, undertakes necessary animal & human clinical trials, and also undertakes training of key personnel as and when required. HNPL has tie up with some of the reputed Indian Companies for marketing these products. The company is promoted by a group of professionals with large experience in pharma industry.

Technical Tie Ups

HNPL had technical tie ups with UDCT-University Department of Chemical Technology & Pharmaceutics of university of Bombay and NIMS – Nizam’s Institute of medical sciences Hyderabad. This tie up together with the in-house research professionals including toxicologists and Doctorates in pharmaceutics, HNPL carries out toxicological studies, animal trials and human trials of the new molecules / formulations developed, before offering to the market. Besides, senior product management and advertising professionals of the company prepare the entire relevant scientific backup and promo material through secondary research activities.

The first indian company conducted clinical trial for Glucosamine combo

Randomised, Double-Blind, Parallel, Placebo-Controlled Study of Oral Glucosamine, Methylsulfonymethane and their Combination in Osteoarthritis

P.R. Usha and M.U.R. Naidu

Department of Clinical Pharmacology and Therapeutics, Nizam’s Institute of Medical Sciences, Hyderabad, India

Abstract

Objective: Glucosamine, classified as a slow-acting drug in osteoarthritis (SADOA), is an efficacious chondroprotective agent. Methylsulfonylmethane (MSM), the isoxidised from of dimethyl-sulfoxide (DSMO), is an effective natural analgesic and anti-inflammatory agent. The aim of this study was to compare the efficacy and safety of oral glucosamine (Glu) , methylsulfonylmethane (MSM), their combination and placebo in osteoarthritis of the knee.

Patients and design: A total of 118 patients of either sex with mild to moderate osteoarthritis were included in the study and randomized to receive either Glu 500mg, MSM 500mg, Glu and MSM or placebo capsules three times daily for 12 weeks. Patients were evaluated at 0 (before drug administration) ,2,4,8 and 12 weeks post-treatment for efficacy and safety. The efficacy parameters studied were the pain index, the swelling index, visual analogue scale pain intensity, 15m walking time, the Lequesne index, and consumption of rescue medicine.

Results:  Glu, MSM and their combination significantly improved signs and symptoms of osteoarthritis compared with placebo. There was a statistically significant decrease in mean (+ SD )pain index from 1.74 + 0.47 at baseline to 0.65 + 0.71 at week 12 with Glu (p<0.001).MSM significantly decreased the mean pain index from 1.53 + 0.51 to 0.74 + 0.65, and combination treatment  resulted in amore  significant decrease in the mean pain index (1.7 + 0.47 to 0.36 + 0.33; p<0.001). After 12 weeks, the mean swelling index significantly decrease with Glu and MSM, while the decrease in swelling index with combination therapy was greater  (1.43 + 0.63 to 0.14 + 0.35; p<0.05) after 12 weeks. The Combination produced a statistically significant decrease in the Lequence index. All treatments were all tolerated.

Conclusion: Glu, MSM and their combination produced an analgesic and anti-in-flammtory effect in osteoarthritis. Combination therapy showed better efficacy in reducing pain and swelling and in improving the functional ability of joints than the individual agents. All the treatments were well tolerated. The onset of analgesic and anti-inflammatory activity was found to be more rapid with the combination than with Glu. It can be concluded that the Combination of MSM with Glu provides better and more rapid improvement in patients with osteoarthritis.

Osteoarthritis , a degenerative disease, is the most common condition to affect human joints, and is a major cause of morbidity and disability in the elderly. It is primarily a disorder of cartilage with secondary changes in bone. Although paraceatmol and NSAIDs are widely used in the management of osteoarthritis, there is limited evidence that they actually improve the underlying pathology of the disease. Adverse drug reactions are common with NSAIDs, and this factor limits their long-term use.

Acknowledgements

The authors thank Healers Nutraceuticals Private Limited, Chennai, India, for providing a study grant, the research material and the study medication. The authors have no conflicts of interest directly relevant to the content of this study.

Innovative Products

Consequent to the company’ s research activity, HNPL possesses one potentially patent able product and has offered a few First time launches to the medical profession. These products among other qualities,

  • Support Health Initiatives
  • Satisfy unmet Medical needs
  • Fill a Nutritive / Therapeutic Gap
  • Add value to Prescriptions
  • Fulfill the goals of therapy

New Molecules

HNPL were the pioneers to bring the new molecules Glucosamine Sulphate [GS] & Methyl Sulfonyl Methane [MSM] and Squalene in to Indian market. These molecules were offered to the Indian market way back in 1999. Cartiform plus – a powerful combination of Glucosamine Sulphate and Methyl Sulfonyl Methane (500mg each) is the principle brand for Osteo-arthritis, while Cartiform Forte with 750 mg Glucosamine Sulphate serves as the maintenance dose.

15 more products are ready and are in the varying phases of launch. Besides, a dozen more products have been successfully developed and are being clinically tested.

HNPL and associates:

HNPL being a predominantly research oriented company, has commenced manufacturing facilities of these bulk items as well as formulations through technical and financial tie up with resourceful individuals.

In a nutshell, We, at Healers Nutraceuticals (P) Ltd., (HNPL), look after the “Product Innovation” and the customer looks after the marketing.